AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through the mTOR pathway

Yizhi Zhang,Wan Li,Yihui Yang,Sen Zhang,Hong Yang,Yue Hao,Xu Fang,Guanhua Du,Jianyou Shi,Lianqiu Wu,Jinhua Wang
DOI: https://doi.org/10.1186/s12935-023-03191-3
IF: 6.429
2024-02-11
Cancer Cell International
Abstract:Glioblastoma (GBM) is the most common brain tumor with the worst prognosis. Temozolomide is the only first-line drug for GBM. Unfortunately, the resistance issue is a classic problem. Therefore, it is essential to develop new drugs to treat GBM. As an oncogene, Skp2 is involved in the pathogenesis of various cancers including GBM. In this study, we investigated the anticancer effect of AAA237 on human glioblastoma cells and its underlying mechanism.
oncology
What problem does this paper attempt to address?